SCHEMBL793608

SCHEMBL793608

NS(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 9/20 0.69
CA1 P00915 8/20 0.69
CA9 Q16790 6/20 0.69
CA7 P43166 4/20 0.69
CA12 O43570 3/20 0.69
CA4 P22748 3/20 0.69
CA6 P23280 3/20 0.69
CA5A P35218 3/20 0.69
CA14 Q9ULX7 3/20 0.69
CA5B Q9Y2D0 3/20 0.69
VCAM1 P19320 1/20 0.60
CA13 Q8N1Q1 2/20 0.56
CA3 P07451 1/20 0.56
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
PTGS1 P23219 2/20 0.56
PTGS2 P35354 2/20 0.56
PTGES2 Q9H7Z7 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzenesulfonamide SCHEMBL11854954 0.90 CA1 (0.61) CA2CA1CA9CA7CA12
SCHEMBL15831620 0.87 CA2 (0.61) CA2CA1CA9CA7CA12
SCHEMBL248783 0.82 CA1 (1.00) CA2CA1CA9CA7CA12
SCHEMBL29906360 0.82 CA1 (1.00) CA2CA1CA9CA7CA12
SCHEMBL2517351 0.82 CA2 (0.64) CA2CA1CA9CA7CA12
SCHEMBL1803937 0.82 PTGS1 (0.66) CA2CA1CA9CA7CA12
SCHEMBL1803934 0.82 CA2 (0.64) CA2CA1CA9CA7CA12
Clofenamide SCHEMBL310408 0.82 CA1 (0.59) CA2CA1CA9CA7CA12
SCHEMBL5805029 0.82 CA2 (0.61) CA2CA1CA9CA7CA12
SCHEMBL1186046 0.82 CA2 (0.70) CA2CA1CA9CA7CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150322094-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-11-12 US claimed
CN-104903290-A Novel compound having ability to inhibit 11beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient AHN GOOK PHARMACEUTICAL CO LTD 2015-09-09 CN claimed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO claimed
US-20110177046-A1 DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS BETAGENON AB 2011-07-21 US claimed
EP-2183233-A1 DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS Betagenon AB (SE) 2010-05-12 EP claimed
WO-2009019445-A1 DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS BETAGENON AB (SE) 2009-02-12 WO claimed
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-21 US claimed
WO-2008100618-A2 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
WO-2008093919-A1 USE OF N-BENZYL-N-(2-DIMETHYLAMINO-ETHYL)BENZENESULFONAMIDE DERIVATIVES FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS DONGBU HITEK CO., LTD. (KR) 2008-08-07 WO claimed
EP-1648897-A1 N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO FERRER INTERNACIONAL, S.A. (ES) 2006-04-26 EP claimed
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2006-03-16 US claimed
WO-2005014597-A1 N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO FERRER INTERNACIONAL, S.A. (ES) 2005-02-17 WO claimed
EP-1472216-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE Axys Pharmaceuticals (US) 2004-11-03 EP claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 WO claimed
WO-2003063764-A2 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2003-08-07 WO claimed
CN-1090279-A Be used for the treatment of HIV and other retroviral pyran-2-ones and 5,6-dihydropyrane-2-ketone UPJOHN CO (US) 1994-08-03 CN claimed
CN-110143999-B Cytotoxic and antimitotic compounds and methods of use thereof 酵活英属哥伦比亚省公司 2023-12-05 CN disclosed
EP-0226896-A2 Lankacidin derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1987-07-01 EP disclosed
US-4129657-A Imidazole guanidines and use as inhibitors of histamine activity SMITH, KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322094-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS CAT, HSF1, HPD CA2 341/4885CA1 1091/4885CA9 1495/4885
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ CA2 413/4885CA1 573/4885CA9 1806/4885
US-20110177046-A1 DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS TK2, FABP4, TXNRD2 CA2 3272/4885CA1 4337/4885CA9 2306/4885
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 CA2 1297/4885CA1 549/4885CA9 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.